Navigation Links
Accuray Reports Financial Results for First Quarter of Fiscal Year 2014
Date:11/7/2013

GAAP net loss with a non-GAAP measure of adjusted EBITDA. Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the Company and facilitates a more meaningful comparison of results for current periods with previous operating results.  Additionally, it will assist management in analyzing future trends, making strategic and business decisions and establishing internal budgets and forecasts. A reconciliation of non-GAAP adjusted EBITDA to GAAP net loss (the most directly comparable GAAP measure) is provided in the schedule below.

There are limitations in using this non-GAAP financial measure because it is not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies.  This non-GAAP financial measure should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP and the reconciliations of the non-GAAP financial measure provided in the schedule below.

About AccurayAccuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The Company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.

Safe Harbor StatementStatements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities L
'/>"/>

SOURCE Accuray Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Acquisitions, Clinical Trial Results, Date Extensions and Financial Results - Research Report on Endo, Astex, Auxilium, Accuray, and BioScrip
2. Accuray Announces First CyberKnife System in South America
3. Accuray Surpasses 600 Installations Globally
4. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
5. Omeros Corporation Reports Third Quarter 2013 Financial Results
6. Global Positron Emission Tomography Market 2012-2016: Industry Analysis, Size, Share, Growth, Trends and Forecast New Research Report Available at MarketResearchReports.biz
7. Global In Vitro Fertilization Market 2012-2016: Industry Analysis, Size, Share, Growth, Trends and Forecast New Research Report Available at MarketResearchReports.biz
8. Global Biophotonics Market & OSS BSS Industry 2012-2016 Reports
9. China Vanadium Catalyst Market for Sulfuric Acid Production in A New Research Available at MarketReportsChina.com
10. Cytos Biotechnology Ltd Reports Third Quarter 2013 Financial Results and Recent Developments
11. Neurocrine Biosciences Reports Third Quarter 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...   Cypher Genomics, Inc., the leading genome ... SQNM ), the leading molecular diagnostics company, today ... prenatal tests (NIPT). Through this agreement, Sequenom will ... advance analysis of clinically-relevant fetal sub-chromosomal variants detected ...
(Date:1/22/2015)... Jan. 22, 2015   GenoSpace , a precision medicine software ... enable the broad use of genomic, imaging and other biomedical ... of Michelle Munson , CEO of Aspera, an IBM ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 "We are ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 The report ... by Product Type & Provider Type - Global Advancements, ... market with an in-depth analysis and forecasting of revenues. ... spread through 221 pages and in-depth TOC on “Service ...
(Date:12/24/2014)... , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI, ... announced the closing of an underwritten public offering of 3,500,000 ... an aggregate 3,500,000 shares of common stock, at an offering ... warrants have a per share exercise price of $5.00, are ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4GenoSpace Expands Board with Appointment of Michelle Munson 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... CHAPEL HILL, N.C., June 18 To thrive ... need to,understand that a winning sales performance doesn,t ... their sales forces, then,measure the forces, field-performance to ... research study reveals that best-in-class,companies allow their sales ...
... Arsenal Against ... Chronic Wounds, ... provider of advanced wound care products,announced today that its key product, ... by clinicians at Georgetown,University Hospital,s Wound Center to save a patient,s ...
... Pharmaceuticals, Inc., a,privately held biopharmaceutical company specializing in ... ophthalmology, is pleased,to announce the appointment of Dr. ... "I am honored and delighted to join ... as it advances its lead programs through,clinical trials ...
Cached Biology Technology:Increasing Sales Productivity Through Superior Sales Force Performance Management 2Derma Sciences MEDIHONEY(TM) Helps to Save Patient's Limb 2Derma Sciences MEDIHONEY(TM) Helps to Save Patient's Limb 3Derma Sciences MEDIHONEY(TM) Helps to Save Patient's Limb 4Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals 2Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals 3
(Date:12/19/2014)... Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) has announced the ... Apple/AuthenTec TMDR92 & Sapphire - Technology Report" report ... Following the acquisition of AuthenTec in ... the iPhone 5S. It is currently the only device ...
(Date:12/17/2014)... Va. , Dec. 15, 2014 The Defense ... easier to detect and prevent counterfeit microcircuits from entering ... started performing an in-house microcircuit anti-counterfeit initiative dubbed DNA ... microcircuits while increasing their reliability throughout the supply chain. ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ( ... "Global Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used for the ... facial feature of a person such as nose, jaw ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... mediates the body's defense against a wide variety of infectious ... as the result of a new study by researchers at ... "Essentially, we found a way to grease the gears that ... Selma and Herman Seldin Professor of Medicine and director of ...
... expression of a special green-algae gene into neurons ... have been able to elicit specific behavioral responses ... work paves the way for better understanding of ... muscles, to regulate behavior in intact, living organisms. ...
... In a surprise twist that recalls the film classic "Flowers ... statins, a popular class of cholesterol drugs, to reverse the ... disabilities. The Nov. 8 issue of Current Biology reports ... the disease, called neurofibromatosis 1 (NF1). , The ...
Cached Biology News:Greasing interferon's gears may pave way to greater therapeutic benefits, fewer side effects 2Algal protein in worm neurons allows remote control of behavior by light 2Recreating 'Flowers for Algernon' with a happy ending 2Recreating 'Flowers for Algernon' with a happy ending 3